Whether VISION-ineligible patients, as defined by visual PSMA PET/CT read rules,could benefit from 177Lu-PSMA-617 treatment remains untested (as forother PSMA PET selection criteria, such as those used in TheraP) (20,27).Future investigative directions include quantifying the tumor-absorbed dose andnormal organ-absorbed dose, enhancing 68Ga-PSMA-11 PET sensitivity, andstandardizing the reporting of PSMA PET/CT. Here, FOLH1 is linked to neoplasm.